Orexo to present at 2015 Nordic Life Sciences Conference
Uppsala, Sweden – April 22, 2015 – Orexo AB (Nasdaq Stockholm: ORX and US OTCQX: ORXOY) today announced that Nikolaj Sørensen, President and Chief Executive Officer, will present a company overview at the 2015 Nordic Life Sciences Conference hosted by the Trout Group and Pareto Securities in New York, NY, on Monday, April 27, 2015 at 10:00 a.m. Eastern Time. Orexo is a specialty pharma company commercializing Zubsolv® (buprenorphine/naloxone) sublingual tablet (CIII) for maintenance treatment of opioid dependence in the United States and developing improved treatments using proprietary drug delivery technologies in Sweden.
Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv® is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.
Nikolaj Sørensen, President and Chief Executive Officer of Orexo
Tel: +46 (0)70-350 78 88, E-mail: firstname.lastname@example.org
Rhonda Chiger (U.S. investors)
Rx Communications Group, LLC
Tel: 917-322-2569, E-mail: email@example.com
Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 6:15 pm CET on April 22, 2015.